Role of nitric oxide synthase genes in hepatitis E virus infection.

Abstract:

:Hepatitis E virus (HEV) is the most common cause of endemic and epidemic acute hepatitis. A correlation between iNOS, eNOS polymorphisms, levels and severity of disease has been reported, and here, we examined the role of iNOS and eNOS gene polymorphisms and their levels in HEV-related acute viral hepatitis and acute liver failure. Hepatitis E virus-related cases of acute hepatitis (294 patients) and liver failure (82 patients) and age- and sex-matched healthy controls (331 subjects) were included in the study. PCR-RFLP was performed to identify the polymorphisms in the iNOS and eNOS genes. iNOS and eNOS levels were studied using ELISA assays and HEV viral load, genotype and combined effects of iNOS genotype, levels and parameters for disease severity were examined. The frequency of iNOS (CT + TT) and eNOS (GT + TT) genotypes was higher in subjects with liver failure compared with controls. iNOS and eNOS levels in patients with acute liver failure (55.51 ± 6.33 IU/mL, 60.2 ± 3.69) cases were significantly increased as compared to patients with acute viral hepatitis (17.8 ± 6.08 IU/mL, 23.7 ± 6.57) and controls (P < 0.05). A significant positive correlation was observed between the iNOS and eNOS levels in our study population when compared with the severity of disease parameters. Hence, the iNOS C150T polymorphism and the eNOS G894T polymorphism and high levels of iNOS and eNOS are associated with an increased risk of HEV-related acute hepatitis and liver failure. This study supports the possible role of nitric oxide synthase genes (iNOS and eNOS) in determining the severity of HEV infection.

journal_name

J Viral Hepat

authors

Hazam RK,Deka M,Kar P

doi

10.1111/jvh.12186

subject

Has Abstract

pub_date

2014-01-01 00:00:00

pages

671-9

issue

9

eissn

1352-0504

issn

1365-2893

journal_volume

21

pub_type

杂志文章
  • Dietary alterations due to perceptions in acute viral hepatitis lead to sub-optimal calorie intake and increased length of hospitalization.

    abstract::Although there are no dietary restrictions recommended in acute viral hepatitis (AVH), there is an altered food intake, probably because of perceptions and traditional nutritional practices, leading to sub-optimal intake and poorer clinical outcome. Therefore, we aimed to determine nutritional intake of AVH patients b...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2009.01184.x

    authors: Sathiaraj E,Chutke M,Mahurkar S,Nagaraja Rao P,Nageshwar Reddy D

    更新日期:2010-05-01 00:00:00

  • Weight loss during pegylated interferon and ribavirin treatment of chronic hepatitis C*.

    abstract:SUMMARY:Treatment of hepatitis C virus (HCV) infection with interferon (IFN)-alpha, as monotherapy or in combination with ribavirin, is associated with significant side-effects including weight loss. The aim of our study was to describe the evolution of body weight during combination antiviral treatment and to examine ...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2005.00637.x

    authors: Seyam MS,Freshwater DA,O'Donnell K,Mutimer DJ

    更新日期:2005-09-01 00:00:00

  • Prevalence of hepatitis viruses in an anti-human immunodeficiency virus-positive population from Argentina. A multicentre study.

    abstract::The objectives of this study were to investigate the prevalence of infections with hepatotrophic viruses in an anti-human immunodeficiency virus (HIV)-positive population from Buenos Aires and to compare it among the main risk groups for HIV infection. Four hundred and eighty-four consecutive patients attending the HI...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章,多中心研究

    doi:10.1046/j.1365-2893.1999.t01-1-6120135.x

    authors: Fainboim H,González J,Fassio E,Martínez A,Otegui L,Eposto M,Cahn P,Marino R,Landeira G,Suaya G,Gancedo E,Castro R,Brajterman L,Laplumé H

    更新日期:1999-01-01 00:00:00

  • Electronic health record year and country of birth testing and patient navigation to increase diagnosis of chronic viral hepatitis.

    abstract::The United States Preventive Services Task Force recommends hepatitis C testing people born from 1945 to 1965, "birth cohort" as well as hepatitis C and hepatitis B testing people from countries of birth with endemic infection risk. We automated the hospital electronic health record system to test birth cohort and tho...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.13098

    authors: de la Torre A,Ahmad M,Ayoub F,Korogodsky M,Pichardo N,Green L,Montesdeoca A,McDowall P,Danko C

    更新日期:2019-07-01 00:00:00

  • Vaccines and immunotherapies against hepatitis B and hepatitis C viruses.

    abstract::Both hepatitis B and hepatitis C viruses (HBV and HCV) cause chronic infections worldwide that are associated with development of liver diseases ranging from mild liver inflammation to hepatocellular carcinomas. While efficient preventive vaccines are available for HBV, efforts are ongoing to develop one in case of HC...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章,评审

    doi:10.1111/j.1365-2893.2007.00922.x

    authors: Inchauspé G,Michel ML

    更新日期:2007-11-01 00:00:00

  • Preclinical aspects of lamivudine and famciclovir against hepatitis B virus.

    abstract::Chemotherapy for chronic hepatitis B virus (HBV) infection is inherently difficult for a variety of reasons that are related to unusual features of both HBV replication strategy and host cell metabolism. Previous attempts to treat chronic HBV infection using nucleoside analogues have been almost universally disappoint...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章,评审

    doi:10.1046/j.1365-2893.1999.00151.x

    authors: Shaw T,Locarnini SA

    更新日期:1999-03-01 00:00:00

  • High response and re-infection rates among people who inject drugs treated for hepatitis C in a community needle and syringe programme.

    abstract::To achieve WHO hepatitis C virus (HCV) elimination targets by 2030, mathematical models suggest there needs to be significant scale-up of treatment among people who inject drugs (PWID). We tested whether people who actively inject drugs can be recruited and treated successfully through a community needle and syringe p...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.13035

    authors: Schulkind J,Stephens B,Ahmad F,Johnston L,Hutchinson S,Thain D,Ward Z,Vickerman P,Hickman M,Dillon JF

    更新日期:2019-05-01 00:00:00

  • Quantification of viral DNA and liver enzymes in plasma improves early diagnosis and management of herpes simplex virus hepatitis.

    abstract::Herpes simplex virus (HSV) hepatitis is a rare and potential life-threatening disease. The diagnosis of HSV hepatitis is hampered by its indifferent clinical presentation, which necessitates confirmatory laboratory data to identify HSV in the affected liver. However, liver biopsies are often contraindicated in the con...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2010.01352.x

    authors: Beersma MF,Verjans GM,Metselaar HJ,Osterhaus AD,Berrington WR,van Doornum GJ

    更新日期:2011-04-01 00:00:00

  • Altered balance between collagen formation and degradation after successful direct-acting antiviral therapy of chronic hepatitis C.

    abstract::The effect of direct-acting antiviral (DAA) therapy on extracellular matrix (ECM) turnover, a prominent feature of chronic hepatitis C (CHC), is unknown. ECM protein degradation and formation generate fragments reflecting the tissue turnover balance when quantified in the blood. PRO-C3 and PRO-C4 reflect type III and ...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.13416

    authors: Laursen TL,Villesen IF,Leeming DJ,Karsdal MA,Sølund C,Tarp B,Kristensen LH,Holmboe CH,Leutscher P,Laursen AL,Gudmann NS,Grønbaek H

    更新日期:2021-02-01 00:00:00

  • Long-term interferon-alpha treatment of children with chronic hepatitis delta: a multicentre study.

    abstract::We assessed the efficacy of prolonged interferon-alpha (IFN) therapy in children with chronic hepatitis caused by hepatitis delta virus (HDV) by treating 26 paediatric cases with IFN-alpha 2b (5 MU m-2, then 3 MU m-2 three times weekly for 12 (medium-term group MTG) or 24 months (long-term group, LTG). Compliance and ...

    journal_title:Journal of viral hepatitis

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1111/j.1365-2893.1996.tb00002.x

    authors: Di Marco V,Giacchino R,Timitilli A,Bortolotti F,Crivellaro C,Calzia R,Iannuzzi C,Prestileo T,Vajro P,Nebbia G,Stringhi C,Rosina F,Biassoni D,Callea F,Rizzetto M,Craxi A

    更新日期:1996-05-01 00:00:00

  • Impact of eradicating hepatitis C virus on the work productivity of chronic hepatitis C (CH-C) patients: an economic model from five European countries.

    abstract::CH-C negatively affects work productivity (WP), creating a large economic burden. The aim of this study was to model the impact of sustained virologic response (SVR) on WP in CHC genotype 1 (GT1) patients in five European countries (EU5). Work Productivity and Activity Index-Specific Health Problem questionnaire was a...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.12483

    authors: Younossi Z,Brown A,Buti M,Fagiuoli S,Mauss S,Rosenberg W,Serfaty L,Srivastava A,Smith N,Stepanova M,Beckerman R

    更新日期:2016-03-01 00:00:00

  • Hepatitis C: What is the best treatment?

    abstract::The treatment of hepatitis C is expensive, difficult and arduous from the patient's perspective. It is similarly difficult for the clinician to decide who and when to treat. If hepatitis C is viewed from the liver's perspective we need only treat those patients who will develop the complications of chronic liver disea...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章,评审

    doi:10.1111/j.1365-2893.2004.00573.x

    authors: Dillon JF

    更新日期:2004-09-01 00:00:00

  • Hepatitis C virus quasispecies in plasma and peripheral blood mononuclear cells of treatment naïve chronically infected patients.

    abstract::Peripheral blood mononuclear cells (PBMCs) from 45 treatment naïve, HIV-negative, chronically hepatitis C virus (HCV)-infected patients were analyzed for the presence of HCV RNA. Viral RNA was detected in 73% of the studied patients. Single-strand conformation polymorphism assays and sequence analysis of the HCV 5'unt...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2009.01112.x

    authors: Vera-Otarola J,Barría MI,León U,Marsac D,Carvallo P,Soza A,López-Lastra M

    更新日期:2009-09-01 00:00:00

  • Clinical importance of serum hepatitis B surface antigen levels in chronic hepatitis B.

    abstract::Quantitative serology for hepatitis B surface antigen (HBsAg) is a new candidate marker for prediction of clinical outcome. The aim of this study was to investigate the clinical significance of quantifying HBsAg in patients with hepatitis B virus (HBV) infection. A total of 424 patients who tested positive for HBsAg a...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2011.01486.x

    authors: Togo S,Arai M,Tawada A,Chiba T,Kanda T,Fujiwara K,Imazeki F,Yokosuka O

    更新日期:2011-10-01 00:00:00

  • Effectiveness of triple therapy with simeprevir for chronic hepatitis C genotype 1b patients with prior telaprevir failure.

    abstract::Favourable efficacy and safety profiles for simeprevir in combination with pegylated interferon alpha (PEG-IFNα) and ribavirin (triple therapy) have been shown in clinical trials. This study was carried out to evaluate the effectiveness of simeprevir-based triple therapy for patients with prior telaprevir treatment fa...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章,多中心研究

    doi:10.1111/jvh.12427

    authors: Ogawa E,Furusyo N,Dohmen K,Kajiwara E,Kawano A,Nomura H,Takahashi K,Satoh T,Azuma K,Nakamuta M,Koyanagi T,Kotoh K,Shimoda S,Hayashi J,Kyushu University Liver Disease Study (KULDS) Group.

    更新日期:2015-12-01 00:00:00

  • Infection with human herpes virus type 8 in an area at high prevalence for hepatitis C virus infection in southern Italy.

    abstract::The Campania Region is a geographical area of southern Italy characterized by high incidence rates of hepatocellular carcinoma and of classic Kaposi's sarcoma. Epidemiological investigations carried out among different population groups in this region have found high prevalence rates of both hepatitis C virus (HCV) an...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2004.00499.x

    authors: Montella M,Serraino D,Crispo A,Romano N,Fusco M,Goedert JJ

    更新日期:2004-05-01 00:00:00

  • HCV burden of infection in Egypt: results from a nationwide survey.

    abstract::Egypt is the country with the largest hepatitis C virus (HCV) epidemic in the world. In 2008, a Demographic Health Survey (DHS) was carried out in Egypt, providing for the first time a unique opportunity for HCV antibody testing on a nationwide representative sample of individuals. Consenting individuals answered a qu...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2011.01576.x

    authors: Guerra J,Garenne M,Mohamed MK,Fontanet A

    更新日期:2012-08-01 00:00:00

  • Safety and immunogenicity of HBAI20 Hepatitis B vaccine in healthy naïve and nonresponding adults.

    abstract::Approximately 5% of the healthy adult population respond inadequately to the commercial recombinant hepatitis B vaccines. As the recombinant vaccines all have an aluminium-based adjuvant, we tried to enhance the immune response by adding a cytokine-based adjuvant. This new adjuvant AI20, containing 20 μg recombinant h...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章,随机对照试验

    doi:10.1111/jvh.12909

    authors: Koc ÖM,Savelkoul PHM,van Loo IHM,Peeters A,Oude Lashof AML

    更新日期:2018-09-01 00:00:00

  • Kinetics of hepatitis B viral load during 48 weeks of treatment with 600 mg vs 100 mg of lamivudine daily.

    abstract::Oral therapy for chronic hepatitis B remains suboptimal. Mathematical modelling of viral decay kinetics to rapidly assess potential antiviral regimens has proved valuable for human immunodeficiency virus and cytomegalovirus. We defined the kinetics of viral replication in 10 chronic hepatitis B patients randomized to ...

    journal_title:Journal of viral hepatitis

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1111/j.1365-2893.2004.00523.x

    authors: Wang CC,Holte S,Huang ML,Sacks SL,Engelberg R,Ferrenberg J,Shuhart M,Corey L

    更新日期:2004-09-01 00:00:00

  • Validation of connective tissue growth factor (CTGF/CCN2) and its gene polymorphisms as noninvasive biomarkers for the assessment of liver fibrosis.

    abstract::Clinical and experimental studies have demonstrated that connective-tissue growth factor (CTGF) expression is increased in fibrotic human liver and experimental animal models of liver fibrogenesis. CTGF has been linked to transforming growth factor-beta (TGF-beta) pathways in fibroproliferative diseases and specific p...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2009.01110.x

    authors: Kovalenko E,Tacke F,Gressner OA,Zimmermann HW,Lahme B,Janetzko A,Wiederholt T,Berg T,Müller T,Trautwein C,Gressner AM,Weiskirchen R

    更新日期:2009-09-01 00:00:00

  • A randomized trial to assess the efficacy of interferon-alpha daily in combination with ribavirin in the treatment of naïve patients with chronic hepatitis C.

    abstract::A randomized trial was conducted to assess the efficacy of interferon-alpha (IFN) daily in combination with ribavirin in 301 naïve patients with chronic hepatitis C (CHC). Patients were randomized to receive ribavirin 1.2 g daily (QD) for 48 weeks with either IFN 5 MU (thrice weekly) TIW for 8 weeks followed by IFN 3 ...

    journal_title:Journal of viral hepatitis

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1046/j.1365-2893.2003.00439.x

    authors: Tassopoulos NC,Ketikoglou I,Tsantoulas D,Raptopoulou M,Hatzis G,Vafiadis I,Sidiropoulos L,Kanatakis S,Anagnostopoulos G,Sypsa V,Hatzakis A,Hellenic Viral Hepatitis Research Network.

    更新日期:2003-09-01 00:00:00

  • Retreatment for 24 vs 48 weeks with interferon-alpha2b plus ribavirin of chronic hepatitis C patients who relapsed or did not respond to interferon alone.

    abstract::We assessed the efficacy of interferon (IFN) plus ribavirin over 24 or 48 weeks for the retreatment of patients with chronic hepatitis C who had relapsed or did not respond to a previous course of IFN. One-hundred and twenty patients (69 non-responders and 51 relapsers) were randomly assigned to receive IFN-alpha2b (3...

    journal_title:Journal of viral hepatitis

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1046/j.1365-2893.2000.00243.x

    authors: Enríquez J,Gallego A,Torras X,Pérez-Olmeda T,Diago M,Soriano V,Luján MS,García-Samaniego J

    更新日期:2000-11-01 00:00:00

  • Decline in intrahepatic cccDNA and increase in immune cell reactivity after 12 weeks of antiviral treatment were associated with HBeAg loss.

    abstract::Viral load reduction facilitates recovery of antiviral T-cell responses. Dynamic alterations in intrahepatic viraemia clearance and immune cell reactivity during the early phase of nucleoside analogue (NA) therapy and the impact of these changes on HBeAg seroconversion are unknown. Fifteen HBeAg-positive chronic hepat...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.12261

    authors: Zheng Q,Zhu YY,Chen J,Liu YR,You J,Dong J,Zeng DW,Gao LY,Chen LH,Jiang JJ

    更新日期:2014-12-01 00:00:00

  • New HBV subgenotype D9, a novel D/C recombinant, identified in patients with chronic HBeAg-negative infection in Eastern India.

    abstract::Genome diversity is a hallmark of hepatitis B virus (HBV), which allowed its classification into 10 genotypes (A-J) and numerous subgenotypes. Among them, Genotype D is currently segregated into eight subgenotypes (D1-D8). Here, we report the identification and characterization of a novel subgenotype within genotype D...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2012.01655.x

    authors: Ghosh S,Banerjee P,Deny P,Mondal RK,Nandi M,Roychoudhury A,Das K,Banerjee S,Santra A,Zoulim F,Chowdhury A,Datta S

    更新日期:2013-03-01 00:00:00

  • Long-term titrated recombinant interferon-alpha 2a in chronic hepatitis C: a randomized controlled trial.

    abstract::The efficacy and tolerability of 12-month treatment with titrated doses of recombinant interferon-alpha 2a (IFN-alpha 2a) in chronic hepatitis C were studied in 67 consecutively recruited patients randomly assigned either to a starting dose of IFN-alpha 2a 6 MU, subsequently adjusted to the serum alanine aminotransfer...

    journal_title:Journal of viral hepatitis

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1111/j.1365-2893.1995.tb00009.x

    authors: Rumi MG,del Ninno E,Parravicini ML,Romeo R,Soffredini R,Donato MF,Zahm F,Colombo M

    更新日期:1995-01-01 00:00:00

  • Efficacy and safety of entecavir treatment in a heterogeneous CHB population from a ‘real-world’ clinical practice setting in China.

    abstract::Chronic hepatitis B infection is an important cause of liver-related mortality in China. This study assessed the efficacy and safety of entecavir in a heterogeneous patient population from a ‘real-world’ clinical practice setting in China. This prospective, observational cohort provides 48-week data on 2600 patients f...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.12115

    authors: Hou JL,Jia JD,Wei L,Zhao W,Wang YM,Cheng M,Tang X,Tan DM,Ren H,Tang H,Cohen D,Llamoso C

    更新日期:2013-11-01 00:00:00

  • The economics of treating chronic hepatitis C patients with peginterferon alpha-2a (40 kDa) plus ribavirin presenting with persistently normal aminotransferase.

    abstract::Peginterferon alpha-2a (40 kDa) plus ribavirin is effective at achieving sustained viral response compared with no treatment in patients with chronic hepatitis C (CHC) and persistently normal aminotransferase levels (PNALT). The cost-effectiveness of treating CHC in the setting of PNALT has not been assessed. Disease ...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章,随机对照试验

    doi:10.1111/j.1365-2893.2005.00700.x

    authors: Hornberger J,Farci P,Prati D,Zeuzem S,Green J,Patel KK

    更新日期:2006-06-01 00:00:00

  • Role of IL28B and inosine triphosphatase polymorphisms in the treatment of chronic hepatitis C virus genotype 6 infection.

    abstract::IL28B and inosine triphosphatase (ITPA) polymorphisms are able to predict treatment response and degree of ribavirin-related anaemia, respectively, in the treatment of chronic hepatitis C virus (HCV) infection. However, their roles in the treatment of chronic HCV genotype 6 remain undetermined. Sixty patients who were...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.12047

    authors: Seto WK,Tsang OT,Liu K,Chan JM,Wong DK,Fung J,Lai CL,Yuen MF

    更新日期:2013-07-01 00:00:00

  • Fibrosis staging in chronic hepatitis C: analysis of discordance between transient elastography and liver biopsy.

    abstract::In chronic hepatitis C, transient elastography (TE) accurately identifies cirrhosis, but its ability to assess significant fibrosis (Metavir > or = F2) is variable. Constitutional and liver disease-related factors may influence TE and here we examined the variables associated with differences. Three hundred consecutiv...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2009.01199.x

    authors: Calvaruso V,Cammà C,Di Marco V,Maimone S,Bronte F,Enea M,Dardanoni V,Manousou P,Pleguezuelo M,Xirouchakis E,Attanasio M,Dusheiko G,Burroughs AK,Craxì A

    更新日期:2010-07-01 00:00:00

  • Innovative procedures for micro-elimination of HCV infection in persons who use drugs.

    abstract::People who use drugs are a key population in global HCV control. We evaluated the efficacy of an innovative model to eliminate HCV infection in a high-risk population of PWUD in a service for substance use disorder (SUD). Between January 2018 and December 2018, we conducted a prospective, interventional, before and af...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.13375

    authors: Messina V,Russo A,Parente E,Russo G,Raimondo T,Salzillo A,Simeone F,Onorato L,Di Caprio G,Pisaturo M,Coppola N

    更新日期:2020-12-01 00:00:00